Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Core Insights - Olema Pharmaceuticals is set to present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) from December 10-13, 2024 [1] Company Overview - Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other conditions [1][5] - The company is advancing a pipeline of novel therapies, including palazestrant (OP-1250), which is currently in a Phase 3 clinical trial called OPERA-01 [5] Product Information - Palazestrant (OP-1250) is a novel orally available small molecule that acts as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader [4] - It is being investigated for its efficacy in patients with recurrent, locally advanced, or metastatic ER-positive, HER2-negative breast cancer [4] - The drug has received FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after one or more lines of endocrine therapy [4] Clinical Study Details - The upcoming presentation will focus on a Phase 1b/2 study of palazestrant in combination with ribociclib for patients with advanced or metastatic ER+/HER2- breast cancer [2] - The poster session is scheduled for December 11, 2024, from 5:30 to 7:00 p.m. CT [2] Investor Engagement - Olema will hold a conference call on December 10, 2024, at 8:00 a.m. ET to discuss the new data with the investment community [3]